Ovarian High Grade Serous Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Ovarian High Grade Serous Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial evaluating IACS-6274 with or without Bevacizumab and Paclitaxel in adults with advanced solid tumors; the study is cu…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer [Phase 1]
Phase 1 clinical trial assessing different dosing amounts of the drug combination M1774 and ZEN-3694 for recurrent ovarian and endometrial c…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating Bevacizumab in combination with Anetumab Ravtansine or Paclitaxel for refractory ovarian, fallopian tube, …
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer [Phase 2]
A Phase 2 trial sponsored by Emory University is investigating repurposed atovaquone for platinum-resistant ovarian cancer, with recruitment…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]
Clinical trial update reporting results from a Phase 1/2 study of ruxolitinib phosphate in combination with paclitaxel and carboplatin for S…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents [Phase 2]
Phase 2 study comparing standard of care versus a triplet targeted immunotherapy combination in Fallopian tube mucinous adenocarcinoma and o…